This discussion emphasizes practical implementation. Freedland outlines how urologists and medical oncologists can collaborate to ensure timely therapy initiation and shares insights into patient- and ...
The ExactVu micro-ultrasound platform is noninferior to MRI in detecting clinically significant prostate cancer in biopsy-naïve men. Microultrasonography offers a cost-effective, in-office alternative ...
Nanopath's assay for cUTIs has received FDA breakthrough device designation, indicating its potential to significantly advance UTI diagnosis. The assay aims to deliver molecular results in 15 minutes, ...
Treatment intensification with ARPIs and chemotherapy has transformed mCSPC management, expanding the urologist's role in early treatment phases. Darolutamide is highlighted for its favorable safety ...
Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation. In this video, urologist Jonathan Henderson, MD, of Arkansas Urology in Little Rock, reflects on ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...
Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...
Niraparib addition to abiraterone and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially those with BRCA mutations. The trial emphasized the importance of genomic testing ...
A Lenore Ackerman, MD, discusses a recent guideline amendment that places a greater value on a negative urinalysis in ruling out UTI. The American Urological Association, in collaboration with the ...
Experts discuss the ways in which AI could transform patient care and improve physician workflows, particularly for benign prostatic hyperplasia.
The TOBY Test uses AI and gas chromatography–mass spectrometry to analyze urine for early cancer detection, offering a significant advantage over current methods. The FDA's breakthrough device ...
"At the end of the day, it's going to be unlikely that we're going to use a single therapy for all of our patients," says Vignesh T. Packiam, MD. There has been an explosion of treatment options in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback